{"filing":{"accession_number":"0001104659-26-099247","cik":"0000001800","ticker":"ABT","company_name":"ABBOTT LABORATORIES","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"tm2623675d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926099247/tm2623675d1_8k.htm"},"events":[{"id":28917,"run_id":26463,"accession_number":"0001104659-26-099247","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"summary":"Abbott announced settlement of material litigation involving specialty formulas for preterm infants, resolving the Gill case (which had a $495 million jury verdict in July 2024) and claims on behalf of approximately 2,000 other individuals for an aggregate settlement amount of approximately $670 million, with approximately 1,700 pending lawsuits involving approximately 12,700 individual infants remaining.","company_name":"ABBOTT LABORATORIES","ticker":"ABT","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":31011,"accession_number":"0001104659-26-099247","item_number":"7.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"Abbott announced settlement of material litigation involving specialty formulas for preterm infants, resolving the Gill case (which had a $495 million jury verdict in July 2024) and claims on behalf of approximately 2,000 other individuals for an aggregate settlement amount of approximately $670 million. This is a material litigation settlement that would significantly affect a reasonable investor's assessment of Abbott's financial position and legal exposure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:35:40.616669+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31012,"accession_number":"0001104659-26-099247","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"Abbott disclosed settlement agreements resolving the Gill lawsuit (which carried a $495 million jury verdict affirmed on appeal) and NEC claims on behalf of approximately 2,000 additional infants for an aggregate settlement amount of approximately $670 million. This represents a material litigation settlement that would significantly affect a reasonable investor's assessment of the company's financial position and legal exposure, particularly given the remaining ~1,700 pending lawsuits involving approximately 12,700 individual infants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:35:40.616669+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31011,"accession_number":"0001104659-26-099247","item_number":"7.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"Abbott announced settlement of material litigation involving specialty formulas for preterm infants, resolving the Gill case (which had a $495 million jury verdict in July 2024) and claims on behalf of approximately 2,000 other individuals for an aggregate settlement amount of approximately $670 million. This is a material litigation settlement that would significantly affect a reasonable investor's assessment of Abbott's financial position and legal exposure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:35:40.616669+00:00","company_name":"ABBOTT LABORATORIES","ticker":"ABT","filing_date":"2026-08-20"},{"id":31012,"accession_number":"0001104659-26-099247","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"Abbott disclosed settlement agreements resolving the Gill lawsuit (which carried a $495 million jury verdict affirmed on appeal) and NEC claims on behalf of approximately 2,000 additional infants for an aggregate settlement amount of approximately $670 million. This represents a material litigation settlement that would significantly affect a reasonable investor's assessment of the company's financial position and legal exposure, particularly given the remaining ~1,700 pending lawsuits involving approximately 12,700 individual infants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:35:40.616669+00:00","company_name":"ABBOTT LABORATORIES","ticker":"ABT","filing_date":"2026-08-20"}]}